Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Completed 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5Thoracic 2Other hematologic neoplasm 2Dermatologic 2Breast 2Sarcoma 1Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Neuroblastoma 3Ganglioneuroblastoma 2Gliosarcoma 1Glioblastoma 1

Interventions

Magnetic Resonance Spectroscopy 73Temozolomide 68Specimen Handling 48Radiotherapy 40Radiosurgery 29Bevacizumab 26Radiation 25Cyclophosphamide 25Nivolumab 21Biopsy 21pembrolizumab 20Carboplatin 16X-Rays 14Lomustine 13Ipilimumab 13fludarabine 12Irinotecan 12Vincristine 11Topotecan 11Surgical Procedures, Operative 11Cisplatin 11Blood Specimen Collection 11trametinib 9dinutuximab 9Immunoglobulin G 8Etoposide 8Doxorubicin 8lutetium Lu 177 dotatate 7fludarabine phosphate 7atezolizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
sargramostim × CNS × 90 days × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT01857934 2026-04-16

Therapy for Children With Advanced Stage Neuroblastoma

St. Jude Children's Research Hospital

Phase 2 Completed
153 enrolled 12 charts
CNS

Neuroblastoma

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Roswell Park Cancer Institute

Phase 2 Active not recruiting
66 enrolled 11 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT06450041 2026-03-23

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

New Approaches to Neuroblastoma Therapy Consortium

Phase 2 Recruiting
62 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡